Literature DB >> 11737130

The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare.

A K Joseph1, T L Mark, C Mueller.   

Abstract

BACKGROUND: Nonmelanoma skin cancer (NMSC) prevalence and treatment costs are rapidly increasing at an unknown rate.
OBJECTIVE: To determine actual prevalence and treatment costs for NMSC in patients over 65 years of age covered by Medicare.
METHODS: We used a 5% random sample of Medicare claims available for 1994 and 1995. Demographic characteristics, period prevalence, treatment types and frequencies, treating physician specialty, and allowable treatment charges associated with the diagnosis of NMSC were analyzed and described.
RESULTS: More than 789,000 patients over age 65 covered by Medicare had a diagnosis and treatment for NMSC in 1995. Fifty-eight percent were men and 98% were Caucasian. The majority were from the South and West regions of the United States. Dermatologists treated more than 60% of these NMSCs. Treatment costs were approximately $285 million. The largest percentage of treatment expenditures (34%) was for excisions.
CONCLUSION: The number of patients with NMSC is far greater than previous estimates. Dermatologists treat the majority of NMSCs. The mean treatment cost per patient is $329. Total expenditures for NMSC eradication represent 0.7% of the Medicare budget. NMSC is a major public health concern because of its increasing prevalence, costs, and the aging U.S. population.

Entities:  

Mesh:

Year:  2001        PMID: 11737130     DOI: 10.1046/j.1524-4725.2001.01106.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  17 in total

1.  Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).

Authors:  Melody J Eide; Martin A Weinstock; Raymond G Dufresne; Suleka Neelagaru; Patricia Risica; Gary J Burkholder; David Upegui; Katharine A Phillips; Bruce K Armstrong; Leslie Robinson-Bostom
Journal:  J Invest Dermatol       Date:  2005-02       Impact factor: 8.551

2.  Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin.

Authors:  Yira Bermudez; Steven P Stratton; Clara Curiel-Lewandrowski; James Warneke; Chengcheng Hu; George T Bowden; Sally E Dickinson; Zigang Dong; Ann M Bode; Kathylynn Saboda; Christine A Brooks; Emanuel F Petricoin; Craig A Hurst; David S Alberts; Janine G Einspahr
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-01

3.  EGFR expression in advanced head and neck cutaneous squamous cell carcinoma.

Authors:  Larissa Sweeny; Nichole R Dean; J Scott Magnuson; William R Carroll; Emily E Helman; Stephen O Hyde; Renee L Desmond; Eben L Rosenthal
Journal:  Head Neck       Date:  2011-07-07       Impact factor: 3.147

4.  Exclusive development of a single type of keratinocyte skin cancer: evidence from an Australian population-based cohort study.

Authors:  Ulrike Keim; Jolieke C van der Pols; Gail M Williams; Adèle C Green
Journal:  J Invest Dermatol       Date:  2014-09-18       Impact factor: 8.551

5.  DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma.

Authors:  Cailing Yang; Dapeng Wu; Jinling Jia; Dong Liu; Zhanguo Li; Chunxiao Zhang; Min Li; Yonghua Xia
Journal:  Tumour Biol       Date:  2013-04-28

Review 6.  Health economic evaluation of non-melanoma skin cancer and actinic keratosis.

Authors:  Mitchell K Higashi; David L Veenstra; Paul C Langley
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Disparities in prevalence rates for lung, colorectal, breast, and prostate cancers in Medicaid.

Authors:  C Daniel Mullins; Jesse L Cooke; Junling Wang; Fadia T Shaya; Doren Van Hsu; Sandra Brooks
Journal:  J Natl Med Assoc       Date:  2004-06       Impact factor: 1.798

8.  Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults.

Authors:  Emilie Lanoy; Dominique Costagliola; Eric A Engels
Journal:  Int J Cancer       Date:  2010-04-01       Impact factor: 7.396

9.  Traditional versus streamlined management of basal cell carcinoma (BCC): A cost analysis.

Authors:  Xinyuan Wu; Elena B Elkin; Chih-Shan Jason Chen; Ashfaq Marghoob
Journal:  J Am Acad Dermatol       Date:  2015-09-02       Impact factor: 11.527

10.  CD147 expression in advanced cutaneous squamous cell carcinoma.

Authors:  Larissa Sweeny; Nichole R Dean; John W Frederick; J Scott Magnuson; William R Carroll; Renee A Desmond; Eben L Rosenthal
Journal:  J Cutan Pathol       Date:  2012-05-11       Impact factor: 1.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.